Greek term (edited): �������������

High-dose methotrexate (HDM) given concurrently with oral 6-mercaptopurine (6 MP) may be followed by myelotoxicity, which may necessitate treatment interruption and thus interfere with the efficacy of the treatment of childhood acute lymphoblastic leukemia (ALL). Through inhibition of purine de novo synthesis and enhancement of the bioavailability, HDM may increase the incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6 MP.A total of 26 children diagnosed 3/1996-4/2001 with ALL received five courses of HDM (5 g/m(2)/24 h with leucovorin rescue) at 8 weeks intervals during their first year of maintenance therapy with oral methotrexate (20 mg/m(2)/week) and 6MP (75 mg/m(2)/day).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&d...

--------------------------------------------------
Note added at 6 mins (2004-03-19 20:01:38 GMT)
--------------------------------------------------

....
This study explored the application of a new treatment protocol, consisting of 2 injections of 153Sm-EDTMP (37 MBq/kg of body weight each), separated by a period of at least 6 weeks, in patients with prostate cancer. The patients’ response was excellent (86% after the 2nd injection) with non-significant myelotoxicity. Only 3 patients (out of 22) exhibited signs of myelotoxicity, which manifested itself mainly as a temporary depression of platelet counts.....
http://users.med.auth.gr/~fgrammat/magazine/eng/jan02/resear...